• 1
    Lebrec D, Noucl O, Corbic M, Benhamou JP. Propranolol—a medical treatment for portal hypertension? Lancet 1980; 2 (8187): 180182.
  • 2
    D'Amico G, Pagliaro L, Bosch J. The treatment of portal hypertension: a meta-analytic review. Hepatology 1995; 22: 332354.
  • 3
    D'Amico G, Pagliaro L, Bosch J. Pharmacological treatment of portal hypertension: an evidence-based approach. Semin Liver Dis 1999; 19: 475505.
  • 4
    Viallet A, Marleau D, Huet M, Martin F, Farley A, Villeneuve JP, et al. Hemodynamic evaluation of patients with intrahepatic portal hypertension. Relationship between bleeding varices and the portohepatic gradient. Gastroenterology 1975; 69: 12971300.
  • 5
    Garcia-Tsao G, Groszmann RJ, Fisher RL, Conn HO, Atterbury CE, Glickman M. Portal pressure, presence of gastroesophageal varices and variceal bleeding. Hepatology 1985; 5: 419424.
  • 6
    Groszmann RJ, Bosch J, Grace ND, Conn HO, Garcia-Tsao G, Navasa M, et al. Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. Gastroenterology 1990; 99: 14011407.
  • 7
    Vorobioff J, Groszmann RJ, Picabea E, Gamen M, Villavicencio R, Bordato J, et al. Prognostic value of hepatic venous pressure gradient measurements in alcoholic cirrhosis: a 10-year prospective study. Gastroenterology 1996; 111: 701709.
  • 8
    Merkel C, Bolognesi M, Sacerdoti D, Bombonato G, Bellini B, Bighin R, et al. The hemodynamic response to medical treatment of portal hypertension as a predictor of clinical effectiveness in the primary prophylaxis of variceal bleeding in cirrhosis. Hepatology 2000; 32: 930934.
  • 9
    Feu F, Garcia-Pagan JC, Bosch J, Luca A, Teres J, Escorsell A, et al. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. Lancet 1995; 346: 10561059.
  • 10
    Escorsell A, Bordas JM, Castaneda B, Llach J, Garcia-Pagan JC, Rodes J, et al. Predictive value of the variceal pressure response to continued pharmacological therapy in patients with cirrhosis and portal hypertension. Hepatology 2000; 31: 10611067.
  • 11
    Bureau C, Peron JM, Alric L, Morales J, Sanchez J, Barange K, et al. “A la carte” treatment of portal hypertension: adapting medical therapy to hemodynamic response for the prevention of bleeding. Hepatology 2002; 36: 13611366.
  • 12
    Villanueva C, Balanzo J, Novella MT, Soriano G, Sainz S, Torras X, et al. Nadolol plus isosorbide mononitrate compared with sclerotherapy for the prevention of variceal rebleeding. N Engl J Med 1996; 334: 16241629.
  • 13
    Villanueva C, Minana J, Ortiz J, Gallego A, Soriano G, Torras X, et al. Endoscopic ligation compared with combined treatment with nadolol and isosorbide mononitrate to prevent recurrent variceal bleeding. N Engl J Med 2001; 345: 647655.
  • 14
    Groszmann RJ, Garcia-Tsao G. Endoscopic variceal banding vs. pharmacological therapy for the prevention of recurrent variceal hemorrhage: what makes the difference? Gastroenterology 2002; 123: 13881391.
  • 15
    Gariepy L, Fenyves D, Kassissia I, Villeneuve JP. Clearance by the liver in cirrhosis. II. Characterization of propranolol uptake with the multipleindicator dilution technique. Hepatology 1993; 18: 823831.
  • 16
    Dishy V, Sofowora GG, Xie HG, Kim RB, Byrne DW, Stein CM, et al. The effect of common polymorphisms of the beta2-adrenergic receptor on agonist-mediated vascular desensitization. N Engl J Med 2001; 345: 10301035.
  • 17
    Garcia-Tsao G, Grace ND, Groszmann RJ, Conn HO, Bermann MM, Patrick MJ, et al. Short-term effects of propranolol on portal venous pressure. Hepatology 1986; 6: 101106.
  • 18
    Escorsell A, Ferayorni L, Bosch J, Garcia-Pagan JC, Garcia-Tsao G, Grace ND, et al. The portal pressure response to beta-blockade is greater in cirrhotic patients without varices than in those with varices. Gastroenterology 1997; 112: 20122016.
  • 19
    Bosch J, Mastai R, Kravetz D, Bruix J, Gaya J, Rigau J, et al. Effects of propranolol on azygos venous blood flow and hepatic and systemic hemodynamics in cirrhosis. Hepatology 1984; 4: 12001205.
  • 20
    Tarantino I, Abraldes JG, Turnes J, Garcia-Pagan JC, Bosch J, Rodes J. The HVPG-response to pharmacological treatment of portal hypertension predicts prognosis and the risk of developing complications of cirrhosis. J Hepatol 2002; 36 (Suppl 1): 15A.
  • 21
    Bosch J, Mastai R, Kravetz D, Navasa M, Rodes J. Hemodynamic evaluation of the patient with portal hypertension. Semin Liver Dis 1986; 6: 309317.
  • 22
    Groszmann RJ. The hepatic venous pressure gradient: has the time arrived for its application in clinical practice? Hepatology 1996; 24: 739741.
  • 23
    D'Amico G, García-Tsao G, Calès P, Escorsell A, Nevens F, Cestari R, et al. “Diagnosis of Portal Hypertension. How and when?” In: de FranchisR, ed. Portal Hypertension III. Proceedings of the Third Baveno International Consensus Workshop on Definitions, Methodology and therapeutic Strategies. Oxford: Blackwell Science, 2001: 3663.
  • 24
    Bosch J, D'Amico G, García-Pagán JC. Portal hypertension. In: Schiff E, Maddrey W, Sorrell M, eds. Schiff s Diseases of The Liver. 2002 (in press).
  • 25
    Grace ND, Groszmann RJ, Garcia-Tsao G, Burroughs AK, Pagliaro L, Makuch RW et al. Portal hypertension and variceal bleeding: an AASLD single topic symposium. Hepatology 1998; 28: 868880.
  • 26
    Garcia-Pagan JC, Escorsell A, Moitinho E, Bosch J. Influence of pharmacological agents on portal hemodynamics: basis for its use in the treatment of portal hypertension. Semin Liver Dis 1999; 19: 427438.
  • 27
    Bosch J, Abraldes JG, Groszmann RJ. Current management of portal hypertension. J Hepatol 2002 (in press).